Effects of acadesine on the incidence of myocardial infarction and adverse cardiac outcomes after coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group.

The source lists no authors.

Anesthesiology1 Oct 1995Cited by 19 (Europe PMC)

PMID7574044DOI10.1097/00000542-199510000-00004PepBankPUB-07574044

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, a post hoc analysis with a more specific MI definition found lower MI incidence with high-dose acadesine (P = 0.018, alpha = 0.017, corrected for multiple comparisons).
In plain wordsIn coronary bypass patients, a post hoc analysis found fewer heart attacks with high-dose acadesine than with placebo.
Peptide
AICAR (acadesine)
Outcome
DecreasePost hoc myocardial infarction, specific definition
Study
n: not reported in source
Comparator
Placebo
Analysis
Exploratory
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
0.1 mg.kg-1.min-1 plus 5 micrograms/ml cardioplegia · Intravenous infusion and cardioplegic solution · 7 hAs given in this study (human).
Measurements
P value
0.018 NA
post hoc myocardial infarction
Corrected alpha
0.017 NA
multiple comparisons
Source sentences
Summary
the incidence of MI was lower (P = 0.018, alpha = 0.017, corrected for multiple comparisons), as were adverse cardiovascular outcomes (P = 0.002) and CVA (P = 0.02) for patients treated with 0.1 mg.kg-1.min-1 acadesine.
1 context sentence(design, population, supporting numbers)
Summary · context
633 patients undergoing CABG surgery were randomized in a double-blind fashion to receive either placebo (n = 212), low-dose acadesine (0.05 mg.kg-1.min-1, n = 214), or high-dose acadesine (0.1 mg.kg-1.min-1, n = 207)
Report a problemFND-0757404405
02HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, high-dose acadesine reduced adverse cardiovascular outcomes versus placebo in a post hoc analysis.
In plain wordsIn coronary bypass patients, high-dose acadesine reduced adverse heart and blood vessel outcomes versus placebo in a post hoc analysis.
Peptide
AICAR (acadesine)
Outcome
DecreasePost hoc adverse cardiovascular outcomes
Study
n: not reported in source
Comparator
Placebo
Analysis
Exploratory
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
0.1 mg.kg-1.min-1 plus 5 micrograms/ml cardioplegia · Intravenous infusion and cardioplegic solution · 7 hAs given in this study (human).
Measurements
P value
0.002 NA
post hoc cardiovascular outcomes
Source sentences
Summary
the incidence of MI was lower (P = 0.018, alpha = 0.017, corrected for multiple comparisons), as were adverse cardiovascular outcomes (P = 0.002) and CVA (P = 0.02) for patients treated with 0.1 mg.kg-1.min-1 acadesine.
1 context sentence(design, population, supporting numbers)
Summary · context
633 patients undergoing CABG surgery were randomized in a double-blind fashion to receive either placebo (n = 212), low-dose acadesine (0.05 mg.kg-1.min-1, n = 214), or high-dose acadesine (0.1 mg.kg-1.min-1, n = 207)
Report a problemFND-0757404406
03HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, high-dose acadesine had lower post hoc stroke incidence versus placebo (P = 0.02).
In plain wordsIn coronary bypass patients, high-dose acadesine had fewer strokes than placebo in a post hoc analysis (P = 0.02).
Peptide
AICAR (acadesine)
Outcome
DecreasePost hoc cerebrovascular accident
Study
n: not reported in source
Comparator
Placebo
Analysis
Exploratory
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
0.1 mg.kg-1.min-1 plus 5 micrograms/ml cardioplegia · Intravenous infusion and cardioplegic solution · 7 hAs given in this study (human).
Measurements
P value
0.02 NA
post hoc cerebrovascular accident
Source sentences
Summary
the incidence of MI was lower (P = 0.018, alpha = 0.017, corrected for multiple comparisons), as were adverse cardiovascular outcomes (P = 0.002) and CVA (P = 0.02) for patients treated with 0.1 mg.kg-1.min-1 acadesine.
1 context sentence(design, population, supporting numbers)
Summary · context
633 patients undergoing CABG surgery were randomized in a double-blind fashion to receive either placebo (n = 212), low-dose acadesine (0.05 mg.kg-1.min-1, n = 214), or high-dose acadesine (0.1 mg.kg-1.min-1, n = 207)
Report a problemFND-0757404407
04HumanRandomized controlled trialSafety outcome
In coronary bypass patients, adverse event incidence was similar with acadesine and placebo, except for high-dose uric acid elevation.
In plain wordsIn coronary bypass patients, adverse event rates were similar with acadesine and placebo, except for higher uric acid at high doses.
Peptide
AICAR (acadesine)
Outcome
No significant changeAdverse event incidence
Study
n = 633
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
0.05 or 0.1 mg.kg-1.min-1 plus 5 micrograms/ml cardioplegia · Intravenous infusion and cardioplegic solution · 7 hAs given in this study (human).
Source sentences
Summary
There was a similar incidence of adverse events in the acadesine groups and the placebo group, with the exception that serum uric acid transiently increased in the high-dose acadesine group.
1 context sentence(design, population, supporting numbers)
Summary · context
633 patients undergoing CABG surgery were randomized in a double-blind fashion to receive either placebo (n = 212), low-dose acadesine (0.05 mg.kg-1.min-1, n = 214), or high-dose acadesine (0.1 mg.kg-1.min-1, n = 207)
Report a problemFND-0757404401
05HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, prespecified myocardial infarction incidence did not differ across placebo and both acadesine dose groups.
In plain wordsIn coronary bypass patients, heart attack rates did not differ across placebo and both acadesine dose groups.
Peptide
AICAR (acadesine)
Outcome
No significant changePrespecified perioperative myocardial infarction
Study
n = 633
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
0.05 or 0.1 mg.kg-1.min-1 plus 5 micrograms/ml cardioplegia · Intravenous infusion and cardioplegic solution · 7 hAs given in this study (human).
Measurements
Perioperative MI incidence
24%
three-group comparison, first value listed; group order not stated in the result sentence
Perioperative MI incidence
26%
three-group comparison, second value listed; group order not stated in the result sentence
Perioperative MI incidence
21%
three-group comparison, third value listed; group order not stated in the result sentence
P value
0.574 NA
between the three groups
Source sentences
Summary
The incidence of perioperative MI, using the prespecified MI criterion (EGF Q wave, CK-MB elevation, or autopsy evidence), was not different between groups (24% versus 26% versus 21% [P = 0.574])
1 context sentence(design, population, supporting numbers)
Summary · context
633 patients undergoing CABG surgery were randomized in a double-blind fashion to receive either placebo (n = 212), low-dose acadesine (0.05 mg.kg-1.min-1, n = 214), or high-dose acadesine (0.1 mg.kg-1.min-1, n = 207)
Report a problemFND-0757404403
06HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, combined cardiovascular outcome incidence did not differ across placebo and both acadesine dose groups.
In plain wordsIn coronary bypass patients, combined heart and blood vessel outcome rates did not differ across placebo and both acadesine dose groups.
Peptide
AICAR (acadesine)
Outcome
No significant changeAll cardiovascular outcomes
Study
n = 633
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
0.05 or 0.1 mg.kg-1.min-1 plus 5 micrograms/ml cardioplegia · Intravenous infusion and cardioplegic solution · 7 hAs given in this study (human).
Measurements
All cardiovascular outcomes incidence
30%
three-group comparison, first value listed; group order not stated in the result sentence
All cardiovascular outcomes incidence
30%
three-group comparison, second value listed; group order not stated in the result sentence
All cardiovascular outcomes incidence
22%
three-group comparison, third value listed; group order not stated in the result sentence
P value
0.151 NA
between the three groups
Source sentences
Summary
The incidence of perioperative MI, using the prespecified MI criterion (EGF Q wave, CK-MB elevation, or autopsy evidence), was not different between groups (24% versus 26% versus 21% [P = 0.574]), nor was the incidence of all cardiovascular outcomes (30% versus 30% versus 22% [P = 0.151]).
1 context sentence(design, population, supporting numbers)
Summary · context
633 patients undergoing CABG surgery were randomized in a double-blind fashion to receive either placebo (n = 212), low-dose acadesine (0.05 mg.kg-1.min-1, n = 214), or high-dose acadesine (0.1 mg.kg-1.min-1, n = 207)
Report a problemFND-0757404404
07HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients, acadesine did not change myocardial infarction incidence assessed by Holter or transesophageal echocardiography versus placebo.
In plain wordsIn coronary bypass patients, acadesine did not change heart attack incidence measured by Holter or transesophageal echocardiography compared with placebo.
Peptide
AICAR (acadesine)
Outcome
No significant changeMyocardial infarction incidence by Holter or echocardiography
Study
n = 633
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
0.05 or 0.1 mg.kg-1.min-1 plus 5 micrograms/ml cardioplegia · Intravenous infusion and cardioplegic solution · 7 hAs given in this study (human).
Source sentences
Summary
No differences were found in the incidence or characteristics of MI (Holter or transesophageal echocardiography).
1 context sentence(design, population, supporting numbers)
Summary · context
633 patients undergoing CABG surgery were randomized in a double-blind fashion to receive either placebo (n = 212), low-dose acadesine (0.05 mg.kg-1.min-1, n = 214), or high-dose acadesine (0.1 mg.kg-1.min-1, n = 207)
Report a problemFND-0757404410
08HumanRandomized controlled trialSafety outcome
In coronary bypass patients, high-dose acadesine transiently increased serum uric acid versus placebo.
In plain wordsIn coronary bypass patients, high-dose acadesine temporarily increased blood uric acid compared with placebo.
Peptide
AICAR (acadesine)
Outcome
IncreaseSerum uric acid
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
0.1 mg.kg-1.min-1 plus 5 micrograms/ml cardioplegia · Intravenous infusion and cardioplegic solution · 7 hAs given in this study (human).
Source sentences
Summary
There was a similar incidence of adverse events in the acadesine groups and the placebo group, with the exception that serum uric acid transiently increased in the high-dose acadesine group.
1 context sentence(design, population, supporting numbers)
Summary · context
633 patients undergoing CABG surgery were randomized in a double-blind fashion to receive either placebo (n = 212), low-dose acadesine (0.05 mg.kg-1.min-1, n = 214), or high-dose acadesine (0.1 mg.kg-1.min-1, n = 207)
Report a problemFND-0757404402
09HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients with Q-wave infarction, high-dose acadesine lowered peak median CK-MB versus placebo.
In plain wordsIn coronary bypass patients with Q-wave heart attacks, high-dose acadesine lowered the peak heart injury marker compared with placebo.
Peptide
AICAR (acadesine)
Outcome
DecreasePeak median CK-MB in Q-wave infarction
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
0.1 mg.kg-1.min-1 plus 5 micrograms/ml cardioplegia · Intravenous infusion and cardioplegic solution · 7 hAs given in this study (human).
Measurements
P value
0.042 NA
peak median CK-MB
Source sentences
Summary
In patients with Q-wave infarction, the high-dose acadesine group had a lower peak median CK-MB (P = 0.042) and area under the CK-MB curve (P = 0.021).
1 context sentence(design, population, supporting numbers)
Summary · context
633 patients undergoing CABG surgery were randomized in a double-blind fashion to receive either placebo (n = 212), low-dose acadesine (0.05 mg.kg-1.min-1, n = 214), or high-dose acadesine (0.1 mg.kg-1.min-1, n = 207)
Report a problemFND-0757404408
10HumanRandomized controlled trialEfficacy outcome
In coronary bypass patients with Q-wave infarction, high-dose acadesine lowered CK-MB area under the curve versus placebo.
In plain wordsIn coronary bypass patients with Q-wave heart attacks, high-dose acadesine reduced cumulative heart injury marker levels compared with placebo.
Peptide
AICAR (acadesine)
Outcome
DecreaseCK-MB area under curve in Q-wave infarction
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
0.1 mg.kg-1.min-1 plus 5 micrograms/ml cardioplegia · Intravenous infusion and cardioplegic solution · 7 hAs given in this study (human).
Measurements
P value
0.021 NA
CK-MB area under curve
Source sentences
Summary
In patients with Q-wave infarction, the high-dose acadesine group had a lower peak median CK-MB (P = 0.042) and area under the CK-MB curve (P = 0.021).
1 context sentence(design, population, supporting numbers)
Summary · context
633 patients undergoing CABG surgery were randomized in a double-blind fashion to receive either placebo (n = 212), low-dose acadesine (0.05 mg.kg-1.min-1, n = 214), or high-dose acadesine (0.1 mg.kg-1.min-1, n = 207)
Report a problemFND-0757404409

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.